Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Only stories explicitly associated with this stock are shown.
The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.
The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
GILD is currently shown at $147.68 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
A quantitative forecast is not currently available for GILD.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
There is not yet enough mature evaluation data on this page to claim a verified accuracy rate.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.